Vi Partners led the Series A round of LeaseTeq, a company on a mission to offer the world’s most convenient and smart way to lease any car, anywhere.
2023 is behind us and what a year it was. Let’s review the year in digital healthcare investing and find out how much we achieved, despite the challenging environment.
Successful closing of Series A financing round LeaseTeq and Vi Partners are thrilled to announce the successful completion of a Series A financing round – a pivotal moment in the journey to redefine leasing through cutting-edge technology. With CHF 8m in a first closing and CHF 10m total round size.
Unique AG, the Swiss-based AI-driven FinanceGPT company, announced an official go-live with their client Pictet Group. This rollout enables over 5,000 employees to experience the power of One.Chat, a platform co-developed together with Pictet that allows easy access to all internal information.
Altoida announced today results from the RADAR-AD consortium study, published in Nature Digital Medicine, which evaluated its augmented reality (AR) and machine learning (ML)-based digital cognitive assessment for the early identification of individuals with Alzheimer’s Disease (AD).
The Vi Partners CEO Day was a vibrant gathering of innovative minds and spirited discussions. We were honoured to host our portfolio companies' founders, our esteemed investors, and various key players from the ecosystem.
Araris, the Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.
The developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from the ALIGN-AR Pivotal Trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR).
Leading Berlin-based software provider Ninox is setting a milestone in the world of business applications with the market launch of Ninox CRM. Thanks to low-code, the flexible and individually customizable complete solution allows the continuous digitization of processes on a single platform.
At Vi Partners, we're not just about crunching numbers; we're treasure hunters. What are we digging for? The future leaders of the B2B SaaS universe, particularly in Europe and Switzerland.
Funding extends Xeltis’ Series D2 financing round to €44.5 million.
OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery Once daily OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery OPTIMIZE’s results follow the positive and statistically significant top line results from stage 1 of the Phase 3 DIAMOND trial in Diabetic Macular Edema (DME) reported earlier this year, further highlighting the product’s potential for treating front- and back-of-the-eye diseases
Last year, Vi Partners led a Series A2 round in Vara (www.vara.ai), a pioneering company focused on democratising breast cancer screening and improving women's healthcare outcomes. We are thrilled to partner with Vara's exceptional team, who are driven by the ambition to transform how breast cancer screenings are conducted, ensuring accessibility, accuracy, and a patient-centric approach.
Giving European Healthcare enterprises, a digital upgrade is hard. Let’s explore the challenges and some of the lights on the horizon. The prosperity and health of all of us depends on keeping our health care systems effective. To make sure this is achieved and remains affordable, we need to leverage digital transformation.
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
Last summer, the Vi Partners technology team led a pre-seed round in Morgen.so. We are delighted to partner with a ground breaking time management application built by a stellar team that has the ambition to transform how knowledge workers deal with their time, boost their productivity while improving their worklife balance and overall wellbeing.
Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, announces that it has raised €32 million in a Series D2 equity fundraise.
The Swiss AI start-up Acodis closed a CHF 6m financing round from existing and new investors. Acodis, the leading Intelligent Document Processing (IDP) platform, raised CHF 6 million in a Series A funding round led by Hi Inov and VI Partners. The new funds will be used to further expand Acodis' position as the leading Document Processing Platform for the Pharma and Health sector.
Entrepreneurs improve the world. We proudly support them.
Vi Partners' founding team came together in 2000 to advise Venture Incubator, an investment vehicle initiated by ETHZ and funded by ten blue-chip Swiss companies. Today, we advise funds investing across Europe in tech and healthcare.